Business Wire

Calvin Klein Fragrances announces ROSALÍA as the face of new euphoria elixirs

19.2.2026 14:30:00 CET | Business Wire | Press Release

Share

Calvin Klein, Inc., part of PVH Corp. [NYSE: PVH], and Calvin Klein Fragrances, a division of Coty Inc. [NYSE: COTY], today unveil GRAMMY® Award-winning singer-songwriter ROSALÍA as the face of euphoria elixirs, a new collection of three distinct parfum intense creations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219549836/en/

Calvin Klein Fragrances announces ROSALÍA as the face of new euphoria elixirs.

A daring new chapter of the iconic euphoria franchise, euphoria elixirs are a sensorial exploration of confidence, pleasure and sensuality. Embodied by global icon and Calvin Klein ambassador ROSALÍA, the campaign fuses movement and vivid color into a captivating exploration of freedom without limits. Known for her genre-defying sound and commanding visual artistry, ROSALÍA channels the fragrances’ modern femininity into an immersive journey that reflects the energy and individuality of the three distinctive scents.

“The euphoria elixirs are full of energy, possibility of expression and versatility!” said ROSALÍA. “Each of the three scents represents its own mood, but the vanilla notes (which I love) run through all of them, giving a warm and familiar feeling on the skin. This reunion with Calvin Klein has been a dream - I love working with teams that are as inspiring and hardworking as them!”

euphoria elixirs introduce premium, ultra-concentrations that celebrate the versatility of their key ingredient, vanilla – soft yet strong, sweet yet seductive. Richly layered and modern in spirit, the assortment takes shape through three vibrant, emotive interpretations: magneticelixir, bold elixir and solar elixir.

The euphoria elixirs collection:
Expressive. Radiant. Confident.

This collection explores vanilla—the fruit of the orchid, euphoria’s signature flower—through its full evolution from its fresh, green beginnings (solar elixir) to its vibrant ripeness (magnetic elixir), and finally to its sun-kissed, dried, and toasted warmth (bold elixir). Each scent pairs a distinct vanilla facet with a complementary note to define a clear mood: solar elixir fuses vanilla with mango for a bright, luminously joyful energy; magnetic elixir layers vanilla with musk for a soft, intimately romantic warmth; and bold elixir contrasts vanilla with oakwood for a deeper, more intense impression.

Co-created with master perfumers from some of the world’s most esteemed fragrance houses, all three scents are parfum intense with 28% or more ultra-concentration – the highest fragrance concentration for Calvin Klein Fragrances.

magnetic elixir (musky vanilla)
magnetic elixir captures the irresistible pull of effortless confidence and sensuality. Anchored by Dancing Lady Orchid, ambrette absolute and an indulgent musky vanilla blend, this rich, sweet fragrance has a seductive charm and lingers like a warm touch.

Perfumer: Caroline Dumur
Fragrance House: IFF

bold elixir (oakwood vanilla)
bold elixir is sensual, woody and addictive, channeling the intensity and rich depth of toasted vanilla. This warmth is contrasted by the unexpected presence of smoky orchid, rich oakwood and jasmine absolute. The result is a daring scent, exuding unapologetic confidence.

Perfumers: Carlos Benaim, Domitille Michalon, Caroline Dumur
Fragrance House: IFF

solar elixir (mango vanilla)
solar elixir is a radiant expression of joy – pure, luminous and full of life. Inspired by the blooming vanilla flower in its rare green and fruity stage, the fragrance is brightened by the warm glow of Golden Orchid and juicy mango. This elixir radiates with vibrant energy, evoking the sensation of skin warmed by the sun.

Perfumer: Nicolas Bonneville
Fragrance House: dsm-firmenich

The Packaging:
The original euphoria bottle remains a timeless, sculptural icon. For the new euphoriaelixirs, this classic design has been reinvented through color – vivid hues of magnetic pink, bold purple and solar yellow reflect youthful energy and individuality. The signature cap has also been infused with monochromatic color for a striking visual parallel to the intense juice.

The Campaign:
Following her Calvin Klein underwear debut in September 2025, ROSALÍA now stars in the Calvin Klein Fragrances campaign for euphoria elixirs, shot by Carlijn Jacobs. Across the visuals, ROSALÍA amplifies the spirit of euphoria – feminine, sensual and confident – through her unique ability to evoke emotion through movement and performance. Set in a surreal, sensorial world, ROSALÍA embodies each elixir’s distinct attitude across magnetic, bold and solar universes as unlimited possibilities of self-expression and freedom come to life.

Availability:
Calvin Klein euphoria elixirs will be available on calvinklein.com and retailers worldwide beginning February 19, 2026.

Available in 100 ml, 50 ml, 30 ml, and 10 ml.

Credits:
Campaign Video & Photographer: Carlijn Jacobs

Music Credits:
artist: ROSALÍA , song:“Dios Es Un Stalker” / album: LUX

Social Media:
@calvinklein

About Calvin Klein
Calvin Klein is one of the world’s leading global fashion lifestyle brands, founded in New York in 1968. Shaped by a way of living that meets culture, the brand’s distinctive, modern aesthetic informs its approach to iconic product design and influential brand storytelling.

Across underwear, jeans, apparel, accessories, home and fragrance, Calvin Klein creates essential pieces that translate its American fashion roots to an international audience. Global retail sales of Calvin Klein products were approximately $9 billion in 2024.

About PVH Corp.
PVH is one of the world’s largest fashion companies, driven by its two iconic brands, Calvin Klein and TOMMY HILFIGER. For more than 140 years, PVH has connected with and inspired consumers globally and now operates in more than 40 countries worldwide. For more information, visit https://www.pvh.com.

Follow us on Instagram and LinkedIn.

About COTY Inc.
Founded in Paris in 1904, Coty is one of the world's largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, and skin and body care. Coty serves consumers around the world, selling prestige and mass market products in over 120 countries and territories. Coty and our brands empower people to express themselves freely, creating their own visions of beauty; and we are committed to protecting the planet. Learn more at coty.com or on LinkedIn and lnstagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260219549836/en/

Contacts

Coty, Inc.: Christyanna Nguyen, Interim PR Director,
Christyanna_Nguyen@cotyinc.com
Calvin Klein, Inc.: Noelia Callejas, Sr. Director, PR, noeliacallejas@ck.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye